Limb-sparing treatment for canine osteosarcoma to be explored in new studyNovember 14, 2023The new research is set to evaluate the effectiveness of a novel drug combination tailored to giant-breed dogs diagnosed with osteosarcoma.
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
Vaccine appears to control canine osteosarcomaJune 25, 2020A research team at the University of Missouri (MU) College of Veterinary Medicine is exploring the use of a patient-specific, precision medicine treatment for bone cancer in dogs,
VPN Plus+ ExclusiveIs immunotherapy the key to wiping out canine cancer?June 24, 2020An intact and functional immune system is essential to protect an organism against invading pathogens and infectious disease. However, the immune system also plays a pivotal role in identifying and eliminating transformed cells that, if left unchecked, would progress to cancer. Clinical evidence of the immune system's ability to control cancer comes from a number of observations in both the veterinary and medical settings. Consider the following examples: Cats receiving chronic immunosuppression following renal transplant have a higher incidence of lymphoma compared with the general feline population1,2 Spontaneous regression of transmissible venereal tumor is associated with an increased proportion of tumor-infiltrating cytotoxic CD8+ T cells3 Canine osteosarcoma patients that develop bacterial infections after limb-sparing surgery experience significantly prolonged survival times.4 The presence of tumor-specific, cytotoxic T cells within tumors, such as ovarian carcinoma, confers a favorable prognosis,5 whereas infiltration with regulatory or suppressor T cells confers a worse prognosis6 These observations, coupled with two decades of experimentation in murine cancer models, indicate that finding ways to initiate, augment, and broaden a patient's antitumor immune response holds promise for the treatment and possible prevention of cancer. Indeed, this is the aim of cancer immunotherapy, and recent advances in this field have …
Tech companies, Auburn University create longest synthetic virus for canine cancer researchNovember 21, 2016Canine bone cancer research is getting a boost thanks to the efforts of a gene synthesis company, Gen9, a software company, Autodesk, and Auburn University. The combined effects of these three groups helped successfully manufacture a synthetic viral genome, called sCAV2.
